Literature DB >> 2147517

Cardiovascular effects of paroxetine.

H Kuhs1, G A Rudolf.   

Abstract

In a double-blind clinical study, electrocardiogram, blood pressure and systolic time intervals were measured in 40 depressive patients treated with either paroxetine (30 mg/day) or amitriptyline (150 mg/day) for 6 weeks. While amitriptyline significantly increased the heart rate, the QTc interval and the PEP/LVET ratio, paroxetine did not alter any of the cardiovascular parameters measured.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2147517     DOI: 10.1007/bf02244107

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  22 in total

1.  Cardiovascular effects of paroxetine, a newly developed antidepressant, in anesthetized dogs in comparison with those of imipramine, amitriptyline and clomipramine.

Authors:  S Yokota; Y Ishikura; H Ono
Journal:  Jpn J Pharmacol       Date:  1987-11

2.  Biochemical effects of the antidepressant paroxetine, a specific 5-hydroxytryptamine uptake inhibitor.

Authors:  D R Thomas; D R Nelson; A M Johnson
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

3.  Bedside technics for the evaluation of ventricular function in man.

Authors:  A M Weissler; W S Harris; C D Schoenfeld
Journal:  Am J Cardiol       Date:  1969-04       Impact factor: 2.778

4.  Clinical efficacy of paroxetine in resistant depression.

Authors:  P Tyrer; C A Marsden; P Casey; N Seivewright
Journal:  J Psychopharmacol       Date:  1987-01       Impact factor: 4.153

5.  The electrocardiographic and antiarrhythmic effects of imipramine hydrochloride at therapeutic plasma concentrations.

Authors:  E G Giardina; J T Bigger; A H Glassman; J M Perel; S J Kantor
Journal:  Circulation       Date:  1979-11       Impact factor: 29.690

Review 6.  Depression, heart disease, and tricyclic antidepressants.

Authors:  S P Roose; A H Glassman; G W Dalack
Journal:  J Clin Psychiatry       Date:  1989-07       Impact factor: 4.384

7.  Cardiovascular effects of amitriptyline, mianserin, zimelidine and nomifensine in depressed patients.

Authors:  C D Burgess; S Montgomery; J Wadsworth; P Turner
Journal:  Postgrad Med J       Date:  1979-10       Impact factor: 2.401

8.  Effect of paroxetine on the electrocardiogram.

Authors:  J G Edwards; A Goldie; S Papayanni-Papasthatis
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

9.  An early clinical phase II evaluation of paroxetine, a new potent and selective 5HT-uptake inhibitor in patients with depressive illness.

Authors:  C Børup; B Meidahl; I M Petersen; A Vangtorp; P le Fèvre Honoré
Journal:  Pharmacopsychiatria       Date:  1982-11

10.  Paroxetine in the treatment of depression. A double-blind multicenter study versus mianserin.

Authors:  C Mertens; H Pintens
Journal:  Acta Psychiatr Scand       Date:  1988-06       Impact factor: 6.392

View more
  7 in total

1.  Cardiovascular effects of fluvoxamine and maprotiline in depressed patients.

Authors:  W Hewer; W Rost; W F Gattaz
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1995       Impact factor: 5.270

2.  Antidepressants and the risk of sudden cardiac death and ventricular arrhythmia.

Authors:  Charles E Leonard; Warren B Bilker; Craig Newcomb; Stephen E Kimmel; Sean Hennessy
Journal:  Pharmacoepidemiol Drug Saf       Date:  2011-07-28       Impact factor: 2.890

Review 3.  Paroxetine. A review of its pharmacology, therapeutic use in depression and therapeutic potential in diabetic neuropathy.

Authors:  S M Holliday; G L Plosker
Journal:  Drugs Aging       Date:  1993 May-Jun       Impact factor: 3.923

4.  Paroxetine : a review of its pharmacology and therapeutic potential in the management of panic disorder.

Authors:  R H Foster; K L Goa
Journal:  CNS Drugs       Date:  1997-08       Impact factor: 5.749

Review 5.  QTc interval prolongation and torsade de pointes associated with second-generation antipsychotics and antidepressants: a comprehensive review.

Authors:  Mehrul Hasnain; W Victor R Vieweg
Journal:  CNS Drugs       Date:  2014-10       Impact factor: 5.749

6.  Risk of Ventricular Arrhythmia with Citalopram and Escitalopram: A Population-Based Study.

Authors:  Elena Qirjazi; Eric McArthur; Danielle M Nash; Stephanie N Dixon; Matthew A Weir; Akshya Vasudev; Racquel Jandoc; Lorne J Gula; Matthew J Oliver; Ron Wald; Amit X Garg
Journal:  PLoS One       Date:  2016-08-11       Impact factor: 3.240

Review 7.  Effects of antidepressants on QT interval in people with mental disorders.

Authors:  Wilbert S Aronow; Tatyana A Shamliyan
Journal:  Arch Med Sci       Date:  2020-05-29       Impact factor: 3.318

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.